Pharmacotherapy considerations in hospitalized patients with COVID-19 pneumonia

Research output: Contribution to specialist publicationArticle

Abstract

The role of the clinical pharmacist has expanded during the coronavirus disease 2019 (COVID-19) crisis. Pharmacists caring for hospitalized patients with pneumonia must simultaneously provide other team members with updated, COVID-19–specific best practices and ensure consistent application of evidence-based ICU practices, with responsibilities including optimizing medication shortages and keeping current with rapidly changing clinical information. It is also important for pharmacists to keep abreast of the unique pharmacotherapy challenges posed by COVID-19 pneumonia, understand the need for glycemic control and the controversial nature of anticoagulation, and be conversant with the medications used in mechanical ventilation. Objective data on COVID-19 therapy are lacking, and a definitive treatment algorithm will remain elusive so long as disagreement abounds.

Original languageEnglish (US)
PagesHS-9-HS-16
Volume45
No7
Specialist publicationU.S. Pharmacist
StatePublished - Jul 1 2020

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Pharmacotherapy considerations in hospitalized patients with COVID-19 pneumonia'. Together they form a unique fingerprint.

Cite this